[
  {
    "ts": "2026-02-07T05:06:52+00:00",
    "headline": "What Pfizer (PFE)'s Monthly GLP-1 Obesity Drug Push Means For Shareholders",
    "summary": "Pfizer recently reported positive Phase 2b results for its monthly injectable obesity drug PF-3944, showing up to 12.3% placebo-adjusted weight loss at 28 weeks and confirming a safety profile consistent with the GLP-1 class. The company now plans more than 20 obesity-related studies in 2026, including 10 Phase 3 trials of PF-3944, underscoring how central obesity treatments have become to Pfizer’s pipeline. We’ll now examine how Pfizer’s push into monthly GLP-1 obesity therapy shapes its...",
    "url": "https://finance.yahoo.com/news/pfizer-pfe-monthly-glp-1-050652151.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "9b583756-20cf-32fe-9652-c77801cc13c2",
      "content": {
        "id": "9b583756-20cf-32fe-9652-c77801cc13c2",
        "contentType": "STORY",
        "title": "What Pfizer (PFE)'s Monthly GLP-1 Obesity Drug Push Means For Shareholders",
        "description": "",
        "summary": "Pfizer recently reported positive Phase 2b results for its monthly injectable obesity drug PF-3944, showing up to 12.3% placebo-adjusted weight loss at 28 weeks and confirming a safety profile consistent with the GLP-1 class. The company now plans more than 20 obesity-related studies in 2026, including 10 Phase 3 trials of PF-3944, underscoring how central obesity treatments have become to Pfizer’s pipeline. We’ll now examine how Pfizer’s push into monthly GLP-1 obesity therapy shapes its...",
        "pubDate": "2026-02-07T05:06:52Z",
        "displayTime": "2026-02-07T05:06:52Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QSfydsi7Q.1zNEN99DbEyw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hi2p7oczHh8yTJraqZcczg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-pfe-monthly-glp-1-050652151.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-pfe-monthly-glp-1-050652151.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]